HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by COOK, J. A. Articles by WESCHE, D. L. Search for Related Content PubMed PubMed Citation Articles by COOK, J. A. Articles by WESCHE, D. L. Related Collections Malaria

LACK OF A PHARMACOKINETIC INTERACTION BETWEEN AZITHROMYCIN AND CHLOROQUINE

A study was conducted to investigate a possible pharmacokinetic interaction between azithromycin and chloroquine. Twenty-four subjects received azithromycin, 1,000 mg a day for three days, followed by a washout period, then azithromycin, 1,000 mg plus chloroquine 600 mg base on days 1 and 2, and azithromycin, 1,000 mg plus chloroquine 300 mg base on day 3 of the final period. A second group of 16 subjects received chloroquine, 600 mg base on days 1 and 2, then 300 mg base on day 3. Blood samples were obtained serially up to 624 hours after the day 3 dose in each period. Log transformed maximum concentration and area under the curve values of azithromycin and chloroquine were compared using 90% confidence intervals calculated from appropriate analysis of variance models. Ninety percent confidence intervals for all pharmacokinetic parameters were contained within the interval 80–125%, which indicates the absence of a clinically relevant pharmacokinetic interaction.

Received June 8, 2005. Accepted for publication November 6, 2005.

Disclosure: The authors wish to disclose that they are currently or were formerly employed by Pfizer Inc., the makers of azithromycin, and hold stock in the company. All are conducting or have conducted research sponsored by Pfizer. This statement is made in the interest of full disclosure and not because the authors consider this to be a conflict of interest.

^* Address correspondence to David L. Wesche, Pfizer Global Research and Development, Michigan Laboratories, Pfizer Inc., 2800 Plymouth Road, Ann Arbor, MI 48105. E-mail: David.Wesche{at}pfizer.com

Authors’ addresses: Jack A. Cook, Edward J. Randinitis, Candace R. Bramson, and David L. Wesche, Pfizer Global Research and Development, Michigan Laboratories, Pfizer Inc., 2800 Plymouth Road, Ann Arbor, MI 48105, Telephone: 734-622-2920, Fax: 734-622-4319, E-mails: Jack.Cook{at}Pfizer.com, Edward.Randinitis{at}pfizer.com, Candace.Bramson{at}Pfizer.com, and David.Wesche{at}pfizer.com.

This article has been cited by other articles:

				A. A. Fossa, T. Wisialowski, J. N. Duncan, S. Deng, and M. Dunne Azithromycin/Chloroquine Combination Does Not Increase Cardiac Instability despite an Increase in Monophasic Action Potential Duration in the Anesthetized Guinea Pig Am J Trop Med Hyg, November 1, 2007; 77(5): 929 - 938. [Abstract] [Full Text] [PDF]

				E. L. Dahl and P. J. Rosenthal Multiple Antibiotics Exert Delayed Effects against the Plasmodium falciparum Apicoplast Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3485 - 3490. [Abstract] [Full Text] [PDF]